Рокситромицин – перспективный антибиотик из класса макролидов


Е.А. Ушкалова

Рокситромицин - перспективный антибиотик из класса макролидов
Рокситромицин представляет собой кислотоустойчивый полусинтетический 14-членный макролид. Препарат активен в отношении грамположительных кокков, возбудителей коклюша, дифтерии, моракселл, легионелл, кампилобактеров, листерий, спирохет, хламидий, микоплазм, уреаплазм, анаэробов и некоторых простейших. Рассматриваются результаты клинических исследований рокситромицина, свидетельствующие о его высокой эффективности при инфекциях различной локализации (органы дыхания, кожа и мягкие ткани, генитальный тракт и т. д.). По своей клинической и бактериологической эффективности при данных инфекциях рокситромицин не уступает другим макролидам, амоксициллину/клавуланату, цефаклору и прочим антибиотикам сравнения или даже превосходит их.

Литература






  1. Guay DR. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-36.
  2. Zara G, Qin XY, Pilot MA, et al. Response of the human gastrointestinal tract to erythromycin. J Gastrointest Motil 1991;3:26-31.
  3. Odenholt-Tornqvist I, Lowdin E, Cars 0. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995;39:221-26.
  4. Bergogne-Berezin E. New pharmacological approaches of macrolides. Example of roxithromycin. Presse Med 1997;26(suppl. 2):4-10.
  5. Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 48:297-326.
  6. Lassman HB, Puri SK, Ho I, et al. Pharmacokinetics of roxithromycin (RU 965). J Clin Pharmacol 1988;28:141-52.
  7. Norrby SR. Safety and drug-drug interactions of macrolides, azalides, and streptogramins. In; New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF (Eds.). New York, etc 1995, p. 61-69.
  8. Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994; 48:297-326.
  9. Hejzlar M, Novotny F, Stastna L, et al. Roxithromycin - a new macrolide derivative. J Hyg Epidemiol Microbiol Immunol 1989;33:487-93.
  10. Begue P, Astruc J. The overall safety of oral roxithromycin in paediatric clinical studies. Infection 1995;23(suppl. 1):S25-27.
  11. Bryskier A. Roxithromycin: review of its antimicrobial activity. Journal of Antimicrobial Chemotherapy 1998;41(suppl. B):1-21.
  12. Hatipoglu ON, Tasan Y. A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. Yonsei Med J 2000;41:340-44.
  13. Chatzimanolis E, Marsan N, Lefatzis D, et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother 1998;41(suppl. B):81-84.
  14. Mira E, Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J Chemother 2001;13:621-27.
  15. Lousbergh D, Jochems G, Everaert L, et al. Roxithromycin versus amoxicillin-clavulanic acid in the treatment of respiratory tract infections. Diagn Microbiol Infect Dis 1992;15(suppl. 4): 91-95S.
  16. de Campora E, Camaioni A, Leonardi M, et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect Dis 1992;15(suppl. 4):119-122S.
  17. Karalus NC, Garrett JE, Lang SD, et al. Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice. Infection 1995;23(suppl. 1):S15-20.
  18. Scott WG, Cooper BC, Scott HM. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study. Infection 1995;23(suppl. 1):S21-24.
  19. Scott WG, Tilyard MW, Dovey SM, et al. Roxithromycin versus cefaclor in lower respiratory tract infection: a general practice pharmacoeconomic study. Pharmacoeconomics 1993; 4: 122-30.
  20. Paulsen O, Christensson BA, Hebelka M, et al. Efficacy and tolerance of roxithromycin in comparison with erythromycin stearate in patients with lower respiratory tract infections. Scand J Infect Dis 1992;24:219-25.
  21. Tatsis G, Tsoukalas G, Boulbasakos G, et al. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. J Antimicrob Chemother 1998;41(suppl. B):69-73.
  22. Salvarezza CR, Mingrone H, Fachinelli H, et al. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998;41(suppl. B):75-80.
  23. Marsac JH. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 1992;15(suppl. 4):S81-84.
  24. Kaku M, Kohno S, Koga H, et al. Efficacy of roxithromycin in the treatment of mycoplasma pneumonia. Chemotherapy 1995;41:149-52.
  25. Durant J, Hazime F, Carles M, et al. Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients. Infection 1995;23(suppl. 1):S33-38.
  26. Uip DE, Lima AL, Amato VS, et al. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J Antimicrob Chemother 1998;41(suppl. B):93-97.
  27. Rosales M, Dominguez V, Bonacho I, et al. Roxithromycin versus doxycycline in the treatment of Chlamydia trachomatis cervicitis in asymptomatic women. Rev Clin Esp 1993;192:253-55.
  28. van Schouwenburg J, de Bruyn O, Fourie E, et al. A randomized, comparative study of the efficacy and tolerance of roxithromycin and doxycycline in the treatment of women with positive endocervical cultures for Chlamydia trachomatis and Mycoplasma spp. in an in vitro fertilization program. Diagn Microbiol Infect Dis 1992;15(suppl. 4):129-131S.
  29. Lidbrink P, Bygdeman S, Emtestam L, et al. Roxithromycin compared to doxycycline in the treatment of genital chlamydial infection and non-specific urethritis. Int J STD AIDS 1993;4:110-13.
  30. Radowicki S, Tyc M, Kulesza E, et al. Roxithromycin (Rulid) in treatment of Chlamydia trachomatis genital infections in women. Ginekol Pol 1995;66:354-56.
  31. Worm AM. Roxithromycin and erythromycin in chlamydia-negative non-gonococcal urethritis. Acta Derm Venereol 1990;70:269-71.
  32. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992;127:155-59.
  33. Agache P, Amblard P, Moulin G, et al. Roxithromycin in skin and soft tissue infections. J Antimicrob Chemother 1987;20(suppl. B):153-56.
  34. Pechere JC. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn Microbiol Infect Dis 1992; 15(suppl. 4):111-117S.
  35. Yamasaki O, Akiyama H, Toi Y, et al. A combination of roxithromycin and imipenem as an antimicrobial strategy against biofilms formed by Staphylococcus aureus. J Antimicrob Chemother 2001;48:573-77.
  36. Ferahbas A, Utas S, Aykol D, et al. Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol 2004;31:6-9.
  37. Deffez JP, Scheimberg A, Rezvani Y, et al. Multicenter double-blind study of the efficacy and tolerance of roxithromycin versus erythromycin ethylsuccinate in acute orodental infection in adults. Odontogenic Infections Study Group. Diagn Microbiol Infect Dis 1992;15(suppl. 4): 133-137S.
  38. Sasaki J, Kaneko A, Takai H, et al. [Clinical evaluation of roxithromycin in odontogenic infection]. Jpn J Antibiot 1989;42:1233-55.
  39. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001;12:1359-68.
  40. Yoshimura T, Kurita C, Yamazaki F, et al. Effects of roxithromycin on proliferation of peripheral blood mononuclear cells and production of lipopolysaccharide-induced cytokines. Biol Pharm Bull 1995;18:876-81.
  41. Takizawa H, Ohtoshi T, Takeuchi N, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998;42:1499-502.
  42. Scaglione F, Rossin, G. Comparative anti-inflammatory effect of roxithromycin, azithromycin and clarithromycin. In Program and Abstracts of the Third International Conference on theMacrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 904, p. 73.
  43. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63.
  44. Amsden GW. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Antimicrob Chemother 2005;55:10-21.
  45. Kita E, Sawaki M, Masaka K, et al. Alterations of host response by a long-term treatment of roxithromycin. J Antimicrob Chemother 1993; 32:285-94.
  46. Morikawa K, Watabe H, Araake M, et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996;40:1366-70.
  47. Black PN. Antinflammatory effects of macrolide antibiotics. Eur Respir J 1997;10:971-72.
  48. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004;8(117 Suppl. 9A):5S-11S. Am J Respir Crit Care Med 2001;164: 536-41.
  49. Mikamo H, Kawazoe K, Izumi K, et al. Effects of long-term administration of roxithromycin on neutrophil count and interleukin-8 level in endometrial cavity subjected to pyometra. Chemotherapy 1997;43:148-52.
  50. Yoshii T, Magara S, Miyai, D, et al. Inhibitory effect of roxithromycin on the local levels of bone-resorbing cytokines in an experimental model of murine osteomyelitis. J Antimicrob Chemother 2002;50:289-92.
  51. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994; 106:458-61.
  52. Black PN, Blasi F, Jenkins Ch R, et al. Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536-41.
  53. Konno S, Asano K, Kurokawa M, et al. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994;105:308-16.
  54. Mayaud C. Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular? Presse Med 1997;26(suppl. 2):27-29.
  55. Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-56.
  56. Sander D, Winbeck K, Klingelhofer J, et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002;106: 2428-33.
  57. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-27.
  58. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:2085-89.





Бионика Медиа